Pınar GÜZEL ÖZDEMİR, Ekrem YILMAZ, Emine YILMAZ

Comparison of paraoxonase, prolidase activities and Hs-CRP, BDNF levels in patients with autogenous and reactive subtypes of obsessive compulsive disorder

Objective: Obsessions have been categorized as autogenous obsessions and reactive obsessions on the original of the cognitive theory and this study aimed to evaluate whether differences are found between obsessive compulsive disorder (OCD) subgroups in terms of biochemical markers. Methods: Thirty patients with obsessions defined as autogenous, 30 patients with obsessions defined as reactive group and 30 healthy volunteers were consisted the sample of the study. Sociodemographic Data Form, Yale-Brown Obsessive Compulsive Scale (Y- BOCS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) were filled to the participants. The activity of paraoxanase, prolidase and Hs-CRP and brain-derived neurotrophic factor (BDNF) levels were detected. Results: There was no any statistically significant difference between autogenous and reactive obsession groups in terms of total mean score of Y-BOCS, BDI and BAI. Paraoxanase activity did not statistically significant difference between all groups. Prolidase activity showed significantly higher in reactive group than autogenous obsession and control groups. Serum Hs-CRP levels were not statistically different among participants of autogenous group, reactive group and control groups. Serum BDNF levels were significantly lower in autogenous obsession group rather than reactive obsession and control groups. Conclusion: This finding indicates that neurobiological pro- cesses have important role in the pathophysiology of autogenous obsessions. (Anatolian Journal of Psychiatry 2019; 20(4):360-367)

Otojen ve reaktif alt tipleri olan OKB hastalarında paraoksonaz, prolidaz aktivitesi ve Hs-CRP, BDNF düzeylerinin karşılaştırılması

Amaç: Obsesyonlar bilişsel kuramın temelinde otojen obsesyonlar ve reaktif obsesyonlar olarak kategorize edilmiş- tir ve bu çalışmada obsesif kompulsif bozukluk (OKB) alt grupları arasında biyokimyasal belirteçler açısından farklılık olup olmadığı araştırılmıştır. Yöntem: Çalışmamıza otojen olarak tanımlanan obsesyonlara sahip 30 hasta, reaktif olarak tanımlanan obsesyonlara sahip 30 hasta ve sağlıklı gönüllülerden oluşan 30 kişi alınmıştır. Katılım- cılara Sosyodemografik Veri Formu, Yale Brown Obsesyon Kompulsiyon Ölçeği (YBOKÖ), Beck Depresyon Ölçeği (BDÖ), Beck Anksiyete Ölçeği (BAÖ) uygulanmıştır. Paraoksonaz (PON1), prolidaz, high sensitif C-reaktif protein (Hs-CRP), beyin kaynaklı nörotrofik faktör (BDNF) düzeyleri ölçülerek karşılaştırılmıştır. Bulgular: Otojen ve reaktif obsesyon grupları arasında YBOKÖ, BDÖ ve BAÖ toplam puan ortalamaları arasında istatistiksel olarak anlamlı bir fark yoktu. Paraoksanaz aktivitesi tüm gruplar arasında istatistiksel olarak anlamlı farklılık göstermedi. Prolidaz aktivitesi reaktif grupta otojen obsesyon ve kontrol gruplarından anlamlı olarak daha yüksek bulundu. Serum HsCRP düzeyleri otojen grup, reaktif grup ve kontrol grubu arasında istatistiksel olarak farklı değildi. Serum BDNF düzeyleri, reaktif obsesyon ve kontrol gruplarından çok, otojen obsesyon grubunda anlamlı olarak daha düşüktü. Sonuç: Bu bulgular, nörobiyolojik süreçlerin otojen obsesyonların patofizyolojisinde önemli rol oynadığını göster- mektedir. (Anadolu Psikiyatri Derg 2019; 20(4):360-367)

PDF

___

American Psychiatric Association. Diagnostic and Statis-tical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association, 2013.

Lochner C, Stein DJ. Heterogeneity of obsessive-com-pulsive disorder: a literature review. Harv Rev Psychiatry 2003;11(3):113-132.

Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epide-miology of obsessive compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15:53-63.

Beşiroğlu L, Uğuz F, Sağlam M, Agargün MY, Aşkın R, Çilli AS. Psychopharmacological treatment response in obsessive compulsive patients with autogenous and reactive obsessions. Bulletin of Clinical Psychopharma-cology 2007; 17(1):1-8.

Batmaz S, Yildiz M, Songur E. Psychopharmacological treatment differences in autogenous and reactive obses-sions: A retrospective chart review. Nord J Psychiatry 2016; 70(1):31-37.

Lee H-J, Kwon S-M. Two different types of obsession: autogenous obsessions and reactive obsessions. Behav Res Ther 2003; 41(1):11-29.

Lee H-J, Kwon S-M, Kwon JS, Telch MJ. Testing the autogenous-reactive model of obsessions. Depression and anxiety 2005; 21(3):118-129.

Fan J, Liu W, Lei H, Cai L, Zhong M, Dong J, et al. Components of inhibition in autogenous- and reactive-type obsessive-compulsive disorder: Dissociation of interference control. Biol Psychol 2016; 117:117-130.

Keleş Altun İ, Uysal E, Özkorumak Karagüzel E. Differ-ences between autogenous and reactive obsessions in terms of metacognitions and automatic thoughts. Neuro-psychiatr Dis Treat 2017; 12:2977-2985.

Lei H, Yi J, Wang H, Zhang X, Dong J, Zho C, et al. Inhi-bitory deficit insemantic conflict in obsessive-compulsive disorder: an event-related potential study. Neuroscience Lett 2013; 552:162-167.

Penadés R, Catalán R, Andrés S, Salamero M, Gasto C. Executive function and nonverbal memory in obsessive-compulsive disorder. Psychiatry Res 2005; 133:81-90.

Leuchter AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM, et al. Biomarkers to predict antidepressant response. Current Psychiatry Reports 2010; 12:553-562.

Beijers L, Wardenaar KJ, Bosker FJ, Lamers F, van Grootheest G, de Boer MK, et al. Biomarker-based sub-typing of depression and anxiety disorders using Latent Class Analysis. A NESDA study. Psychol Med 2018; 4:1-11.

Hu CA, Phang JM, Valle D. Proline metabolism in health and disease. Preface. Amino Acids 2008; 35:651-652.

Demir S, Bulut M, Atli A, Kaplan İ, Kaya MC, Bez Y, et al. Decreased prolidase activity in patients with posttrauma-tic stress disorder. Psychiatry Investig 2016; 13(4):420-426.

Selek S, Altindag A, Saracoglu G, Celik H, Aksoy N. Proli-dase activity and its diagnostic perfor-mance in bipolar disorder. J Affect Disord 2011; 129(1):84-86.

Güneş M, Bulut M, Demir S, İbiloğlu AO, Kaya MC, Atlı A, et al. Diagnostic performance of increased prolidase activity in schizophrenia. Neurosci Lett 2016; 613:36-40.

Hwang J, Brothers RM, Castelli DM, Glowacki EM, Chen YT, Salinas MM, et al. Acute high-intensity exercise-induced cognitive enhancement and brainderived neuro-trophic factor in young, healthy adults. Neurosci Lett 2016; 630:247-253.

Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuro-plasticity. Front Cell Neurosci 2014; 8:430.

Borror A. Brain-derived neurotrophic factor mediates cognitive improvements following acute exercise. Med Hypotheses 2017; 106:1-5.

Alshogran OY, Khalil AA, Oweis AO, Altawalbeh SM, Alqudah MAY. Association of brain-derived neurotrophic factor and interleukin-6 serum levels with depressive and anxiety symptoms in hemodialysis patients. Gen Hosp Psychiatry 2018; 53:25-31.

Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64:527-532.

Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Prickaerts J, Oude Voshaar RC, et al. Gender specific associations of serum levels of brain-derived neuro-trophic factor in anxiety. World J Biol Psychiatry 2012; 13:535-543.

Hall D, Dhilla A, Charalambous A, Gogos JA, Kara-yiorgou M. Sequence variants of the brain-derived neuro-trophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet 200; 73(2):370-376.

Suliman S, Hemmings SM, Seedat S. Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disor-ders: systematic review and meta-regression analysis. Front Integr Neurosci 2013; 7:55.

Oliveira-Maia AJ, Castro-Rodrigues P. Brain-derived neurotrophic factor: a biomarker for obsessive-compul-sive disorder? Front Neurosci 2015; 16:134.

Atli A, Bulut M, Bez Y, Kaplan İ, Özdemir PG, Uysal C, et al. Altered lipid peroxidation markers are related to post-traumatic stress disorder (PTSD) and not trauma itself in earthquake sur-vivors. Eur Arch Psychiatry Clin Neurosci 2016; 266(4):329-336.

Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger G R, et al. The yale-brown obses-sive compulsive scale: II. Validity. Arch Gen Psychiatry 1989; 46(11):1012-1016.

Karamustafalıoğlu O, Üçışık A, Ulusoy M, Erkmen H. Yale-Brown obsesyon-kompulsiyon derecelendirme ölçeğinin geçerlilik ve güvenirlik çalışması. 28. Ulusal Psikiyatri Kongresi 1993, Bursa.

Matsumoto C, Ohmori O, Hori H, Shinkai T, Nakamura J. Analysis of association between the Gln192Arg poly-morphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 2002; 321(3):165-168.

Barim AO, Aydin S, Colak R, Dag E, Deniz O, Sahin İ. Ghrelin, paraoxonase and arylesterase levels in depres-sive patients before and after citalopram treatment. Clinical Biochemistry 2009; 42(10):1076-1081.

Beck AT, Rush AJ, Shaw BF. Cognitive Therapy of Depression. New York: Guilford, 1979.

Hisli N. A study on the validity of Beck Depression Inventory. Journal of Psychology 1988; 6:118-122.

Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Consult Clin Psychol 1988; 56(6):893-897.

Ulusoy M, Sahin N, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cogn Psychother 1998; 12(2):163-172.

Hasler G, LaSalle-Ricci VH, Ronquillo JG, Craw-ley SA, Cochran LW, Kazuba D, et al. Obsessive-compulsive disorder symptom dimensions show specific relation-ships to psychiatric comorbidity. Psychiatry Res 2005; 135(2):121-132.

Lochner C, Hemmings SM, Kinnear CJ, Moolman-Smook JC, Corfield VA, Knowles JA, et al. Gender in obsessive-compulsive disorder: clinical and genetic findings. Euro-pean Neuropsychopharmacology 2004; 14(2):105-113.

Uysal S, Akyol S, Hasgül R, Armutcu, Yiğitoğlu MR. Para-oxonase: A multifaceted enzyme. The New Journal of Medicine 2011; 28(3):136-141.

Kandemir H, Abuhandan M, Aksoy N, Savik E, Kaya C. Oxidative imbalance in child and adolescent patients with obsessive compulsive disorder. J Psychiatr Res 2013; 47(11):1831-1834.

Martin D, Ault B, Nadler JV. NMDA receptor-mediated depolarizing action of proline on CA1 pyramidal cells. Eur J Pharmacol 1992; 219(1):59-66.

Demir S, Bulut M, Atli A, Kaplan I, Ozdemir PG, Bez Y, et al. Is prolidase a neuroprotective molecule in post-traumatic stress disorder? Bulletin of Clinical Psycho-pharmacology 2015; 25(1):167-168.

Hansen-Grant S, Pariante C, Kalin N, Miller A. Neuro-endocrine and immune system pathology in psychiatric disease. Textbook of psychopharmacology. Second ed., Washington, DC: American Psychiatric Press, 1998, pp.171-175.

Luo F, Leckman JF, Katsovich L, Findley D, Grantz H, Tucker DM, et al. Prospective longitudinal study of chil-dren with tic disorders and/or obsessive-compulsive disorder: relationship of symptom exacerbations to newly ac-quired streptococcal infections. Pediatrics 2004; 113:e578-e85.

Wang Y, Mathews CA, Li Y, Lin Z, Xiao Z. Brain-derived neurotrophic factor (BDNF) plasma levels in drug-naïve OCD patients are lower than those in healthy people, but are not lower than those in drug-treated OCD patients. J Affect Disord 2011; 133(1):305-310.

Maina G, Rosso G, Zanardini R, Bogetto F, Gennarelli M, Bocchio-Chiavetto L. Serum levels of brain-derived neurotrophic factor in drug-naive obsessive-compulsive patients: a case-control study. J Affect Disord 2010; 122:174-178.